{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T10:56:52Z","timestamp":1758452212583,"version":"3.44.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF2019M3E5D4064682"],"award-info":[{"award-number":["NRF2019M3E5D4064682"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI19C0189"],"award-info":[{"award-number":["HI19C0189"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.metabol.2022.155311","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T08:37:42Z","timestamp":1663403862000},"page":"155311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database"],"prefix":"10.1016","volume":"138","author":[{"given":"Minyoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeongseob","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Rang","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2022.155311_bb0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155311_bb0010","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.metabol.2022.155311_bb0015","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155311_bb0020","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.metabol.2022.155311_bb0025","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.2337\/dc20-0459","article-title":"Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015\u20132019","volume":"43","author":"Liu","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155311_bb0030","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2022.155311_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2022.155311_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.metabol.2022.155311_bb0045","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.3747\/co.26.4151","article-title":"Diabetes mellitus secondary to treatment with immune checkpoint inhibitors","volume":"26","author":"Venetsanaki","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.metabol.2022.155311_bb0050","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.2337\/dc20-0609","article-title":"Immune checkpoint inhibitor-associated diabetes: a single-institution experience","volume":"43","author":"Byun","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155311_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx815","article-title":"Insulin resistance and body composition in cancer patients","volume":"29","author":"Dev","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.metabol.2022.155311_bb0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.metabol.2022.155311_bb0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events","volume":"6","author":"Davies","year":"2017","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.metabol.2022.155311_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3803\/EnM.2017.32.1.23","article-title":"Acute hyperglycemia associated with anti-cancer medication","volume":"32","author":"Hwangbo","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.metabol.2022.155311_bb0075","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.gastro.2005.05.007","article-title":"Probability of pancreatic cancer following diabetes: a population-based study","volume":"129","author":"Chari","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2022.155311_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/bimj.200710415","article-title":"Youden index and optimal cut-point estimated from observations affected by a lower limit of detection","volume":"50","author":"Ruopp","year":"2008","journal-title":"Biom J"},{"key":"10.1016\/j.metabol.2022.155311_bb0085","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/0049124106292364","article-title":"Advances in group-based trajectory modeling and an SAS procedure for estimating them","volume":"35","author":"Jones","year":"2007","journal-title":"Sociol Methods Res"},{"issue":"6","key":"10.1016\/j.metabol.2022.155311_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu Rev Clin Psychol"},{"key":"10.1016\/j.metabol.2022.155311_bb0095","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0049124101029003005","article-title":"A SAS procedure based on mixture models for estimating developmental trajectories","volume":"29","author":"Jones","year":"2001","journal-title":"Sociol Methods Res"},{"key":"10.1016\/j.metabol.2022.155311_bb0100","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/0898264319852835","article-title":"Seven-year trajectories of depressive symptoms and their predictors among older americans","volume":"32","author":"Xiang","year":"2020","journal-title":"J Aging Health"},{"key":"10.1016\/j.metabol.2022.155311_bb0105","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00592-019-01402-w","article-title":"The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.metabol.2022.155311_bb0110","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/jdi.12531","article-title":"Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy","volume":"7","author":"Okamoto","year":"2016","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.metabol.2022.155311_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.metabol.2017.09.013","article-title":"Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes","volume":"78","author":"Gallo","year":"2018","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2022.155311_bb0120","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc21-2213","article-title":"Immune checkpoint inhibitors and risk of type 1 diabetes","volume":"45","author":"Chen","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155311_bb0125","first-page":"105","article-title":"Cancer causes metabolic perturbations associated with reduced insulin-stimulated glucose uptake in peripheral tissues and impaired muscle microvascular perfusion","author":"Han","year":"2020","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2022.155311_bb0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s43440-020-00179-y","article-title":"Altered glucose metabolism and insulin resistance in cancer-induced cachexia: a sweet poison","volume":"73","author":"Masi","year":"2021","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.metabol.2022.155311_bb0135","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fonc.2019.00218","article-title":"Cancer-induced reprogramming of host glucose metabolism: \u201cVicious cycle\u201d supporting cancer progression","volume":"9","author":"Schwartsburd","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.metabol.2022.155311_bb0140","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0899-9007(01)00561-5","article-title":"Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure","volume":"17","author":"Yoshikawa","year":"2001","journal-title":"Nutrition"},{"key":"10.1016\/j.metabol.2022.155311_bb0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature","volume":"22","author":"Lo Preiato","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.metabol.2022.155311_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042093","article-title":"Immune checkpoint inhibitor-induced diabetes mellitus: potential role of T cells in the underlying mechanism","volume":"22","author":"Mourad","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2022.155311_bb0155","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7861\/clinmed.2020-0054","article-title":"Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?","volume":"20","author":"Kyriacou","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.metabol.2022.155311_bb0160","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3389\/fphar.2019.01453","article-title":"Incidence of immune checkpoint inhibitor-associated diabetes: a meta-analysis of randomized controlled studies","volume":"10","author":"Lu","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2022.155311_bb0165","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3389\/fphar.2019.00726","article-title":"Management of Adverse Events in cancer patients treated with PD-1\/PD-L1 blockade: focus on asian populations","volume":"10","author":"Yang","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2022.155311_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6120113","article-title":"Ethnic similarities and differences in the relationship between Beta cell mass and diabetes","volume":"6","author":"Inaishi","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2022.155311_bb0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4093\/dmj.2021.0045","article-title":"Regulation of pancreatic beta-cell mass by gene-environment interaction","volume":"46","author":"Asahara","year":"2022","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2022.155311_bb0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3803\/EnM.2015.30.3.263","article-title":"Diabetes in Asians","volume":"30","author":"Rhee","year":"2015","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.metabol.2022.155311_bb0185","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.metabol.2022.155311_bb0190","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s00125-012-2607-0","article-title":"Lymphocytes in obesity-related adipose tissue inflammation","volume":"55","author":"Chatzigeorgiou","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155311_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.metabol.2022.155311_bb0200","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.metabol.2022.155311_bb0205","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13539-011-0051-5","article-title":"The role of insulin resistance in the development of muscle wasting during cancer cachexia","volume":"3","author":"Honors","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.metabol.2022.155311_bb0210","first-page":"1699","article-title":"Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer","volume":"23","author":"Kimura","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.metabol.2022.155311_bb0215","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1017\/S0007114508207221","article-title":"Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults","volume":"102","author":"Rush","year":"2009","journal-title":"Br J Nutr"},{"key":"10.1016\/j.metabol.2022.155311_bb0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.maturitas.2009.12.012","article-title":"Ethnic differences in body composition and the associated metabolic profile: a comparative study between asians and caucasians","volume":"65","author":"Wulan","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.metabol.2022.155311_bb0225","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.2337\/dc18-2518","article-title":"T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2022.155311_bb0230","article-title":"Enteral versus parenteral nutrition in cancer patients: evidences and controversies","volume":"5","author":"Cotogni","year":"2016","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.metabol.2022.155311_bb0235","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0962280214543508","article-title":"Double propensity-score adjustment: a solution to design bias or bias due to incomplete matching","volume":"26","author":"Austin","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.metabol.2022.155311_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134140","article-title":"Blood glucose homeostasis in the course of partial pancreatectomy - evidence for surgically reversible diabetes induced by cholestasis","volume":"10","author":"Ehehalt","year":"2015","journal-title":"Plos One"},{"key":"10.1016\/j.metabol.2022.155311_bb0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4093\/dmj.2019.0208","article-title":"Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an asian perspective and expert recommendations","volume":"44","author":"Sheu","year":"2020","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2022.155311_bb0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.metabol.2022.155311_bb0255","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1781333","article-title":"A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy","volume":"9","author":"Peng","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.metabol.2022.155311_bb0260","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2017162","article-title":"Association between immune-related adverse event timing and treatment outcomes","volume":"11","author":"Hsiehchen","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.metabol.2022.155311_bb0265","article-title":"Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED)","volume":"39","author":"Muniz","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2022.155311_bb0270","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2022.155311_bb0275","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5581\/1516-8484.20120010","article-title":"HLA-A, B and DRB1 allele and haplotype frequencies in volunteer bone marrow donors from the north of Parana State","volume":"34","author":"Bardi","year":"2012","journal-title":"Rev Bras Hematol Hemoter"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522001895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522001895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:32:38Z","timestamp":1758429158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049522001895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":55,"alternative-id":["S0026049522001895"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155311","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"155311"}}